BioNTech settles royalty dispute with NIH for $791.5 million

BioNTech SE ((BNTX)) has offered an replace.

BioNTech SE has settled a dispute with the Nationwide Institutes of Well being (NIH) over royalties allegedly owed on gross sales of its COVID-19 vaccine, developed in collaboration with Pfizer. The settlement entails a fee of $791.5 million to the NIH, resolving previous claims and adjusting future royalty agreements. The settlement doesn’t contain any admission of legal responsibility on the a part of BioNTech, and Pfizer has agreed to reimburse $364.5 million of the settlement quantity.

Be taught extra about BioNTech SE

BioNTech SE is a biotechnology firm based mostly in Mainz, Germany, primarily identified for its growth of mRNA-based vaccines and immunotherapies. The corporate is a crucial participant within the pharmaceutical business, notably identified for its collaboration with Pfizer within the manufacturing of the COVID-19 vaccine.

Yr-to-date value efficiency: 7.80%

Common buying and selling quantity: 820 259

Technical Sentiment Consensus Score: Promote

Present market capitalization: $27.28 billion

See extra information on BNTX inventory at TipRanks Stock Analysis Page.